Evaluation of EPI-EE in Eosinophilic Esophagitis: A Study on Tolerability, Toxicity, Pharmacokinetics, and Molecular Mechanisms of Action

The primary objective of this clinical trial is to evaluate the **tolerability**, **toxicity**, and **pharmacokinetics** of EPI-EE in patients with **Eosinophilic Esophagitis**, a chronic inflammatory digestive disease. Understanding these parameters is crucial for determining the safety profile and appropriate dosing regimen of EPI-EE, which may lead to improved management of this condition. The study also aims to investigate the molecular mechanisms of action of EPI-EE, providing insights into its therapeutic potential and contributing to the development of targeted treatments for Eosinophilic Esophagitis.

The clinical trial focuses on **Eosinophilic Esophagitis**, a chronic inflammatory digestive disease. The study population includes both male and female participants, with an age range starting from 3 years old. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been detailed in the available data. Key inclusion or exclusion criteria are also not specified by the sponsor.

The clinical trial is designed to evaluate the **tolerability**, toxicity, pharmacokinetics, and molecular mechanisms of action of EPI-EE in patients with **Eosinophilic Esophagitis**, a chronic inflammatory digestive disease. This trial is a Phase 3 study, which is typically conducted to confirm the effectiveness of a treatment, monitor side effects, and collect information that will allow the treatment to be used safely. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date was May 1, 2021, and the trial is expected to conclude by December 31, 2025, indicating a total duration of approximately four and a half years.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation to ensure participants meet the necessary conditions for inclusion in the study. Following successful screening, participants will be randomly assigned to either the treatment group receiving EPI-EE or a control group. Throughout the trial, participants will attend regular follow-up visits to monitor their health status, assess the drug's effects, and ensure adherence to the study protocol. These visits are crucial for collecting data on the primary and secondary endpoints of the trial.

The end-of-study visit will mark the conclusion of a participant's involvement in the trial. During this visit, final assessments will be conducted to gather comprehensive data on the long-term effects of the treatment. The expected length of participant involvement will vary depending on the individual's response to the treatment and adherence to the study protocol. Conditions that may lead to early termination from the study include adverse reactions to the treatment, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is a Phase 3 study with an estimated recruitment start date of May 1, 2021, and an estimated end date of December 31, 2025. Efficacy will be assessed through the evaluation of primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will likely involve systematic collection and analysis of efficacy parameters at predetermined timepoints throughout the study duration. The methods for measuring and collecting these parameters are not specified, but they typically include validated scales, laboratory tests, or patient-reported outcomes. The analysis will be conducted in accordance with standard clinical trial protocols to ensure the reliability and validity of the results.